ment of patients with at least moderate facial acne vulgaris. J Drugs Dermatol. 2010;9(5):549-558.
12. Tanghetti E, Dhawan S, Green L, et al. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J Drugs Dermatol. 2011;10(7):783-792.
13. Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol. 2008 ;7(6 Suppl):S3-S10.
14. Del Rosso JQ, Tanghetti E. A status report on topical tazarotene in the management of acne vulgaris. J Drugs Dermatol. 2013;12(3):S53-S58.
15. Tanghetti EA, Kircik LH, Green LJ, et al. A Phase 2, Multicenter, Double- Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream (Tazorac®) in the Treatment of Moderate-to-Severe Acne Vulgaris. J Drugs Dermatol. 2019 in press.
16. Zhao Y, Jones SA , Brown MB. Dynamic foams in topical drug delivery. J Pharm Pharmacol. 2010;62:678-684
17. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehiclecontrolled study. Cutis. 1999;63:349-354.
18. Feldman SR, Werner CP, Alio Saenz, AB. The Efficacy and Tolerability of Tazarotene Foam, 0.1%, in the Treatment of Acne Vulgaris in 2 Multicenter, Randomized, Vehicle-Controlled, Double-Blind Studies. J Drugs Dermatol. 2013;12(4):438-446.
12. Tanghetti E, Dhawan S, Green L, et al. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris. J Drugs Dermatol. 2011;10(7):783-792.
13. Thiboutot D, Arsonnaud S, Soto P. Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris. J Drugs Dermatol. 2008 ;7(6 Suppl):S3-S10.
14. Del Rosso JQ, Tanghetti E. A status report on topical tazarotene in the management of acne vulgaris. J Drugs Dermatol. 2013;12(3):S53-S58.
15. Tanghetti EA, Kircik LH, Green LJ, et al. A Phase 2, Multicenter, Double- Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream (Tazorac®) in the Treatment of Moderate-to-Severe Acne Vulgaris. J Drugs Dermatol. 2019 in press.
16. Zhao Y, Jones SA , Brown MB. Dynamic foams in topical drug delivery. J Pharm Pharmacol. 2010;62:678-684
17. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehiclecontrolled study. Cutis. 1999;63:349-354.
18. Feldman SR, Werner CP, Alio Saenz, AB. The Efficacy and Tolerability of Tazarotene Foam, 0.1%, in the Treatment of Acne Vulgaris in 2 Multicenter, Randomized, Vehicle-Controlled, Double-Blind Studies. J Drugs Dermatol. 2013;12(4):438-446.
AUTHOR CORRESPONDENCE
Emil Tanghetti MD et@dermatologyandlasersurgery.com
